Merck invests $70m in new US R&D hub
The pharmaceutical company said the new building will span 145,000 square feet, which will house a new laboratory and collaborative working space that can accommodate approximately 400 new and current R&D employees focused on advancing science in oncology, immuno-oncology and immunology.
“Our talented and passionate R&D teams based in Billerica have been highly engaged in advancing a number of pipeline compounds,” said Luciano Rossetti, head of Global Research & Development at the Biopharma business of Merck. “We continue to strengthen our innovation footprint in both the US and Darmstadt, Germany where our global R&D headquarters are located, with the goal of delivering transformational value to patients around the world.”
Merck has invested more than $150 million in infrastructure to advance biopharmaceutical R&D in Massachusetts recently. It has added more than 150 new jobs to its US R&D Hub in Billerica since 2011.
“Merck’s continued investment in Massachusetts is a testament to the state’s global leadership in life sciences,” said Travis McCready, president and CEO of the Massachusetts Life Sciences Center. “In working collaboratively with the town of Billerica, the company’s campus expansion over the past decade has not only helped attract and retain top talent in the area, but more importantly, contributed to improving the lives of people with serious medical needs.”
The new R&D hub will be completed in 2021. The building will have wet labs, office space and a cafeteria for the campus. It’s seeking LEED and WELL certifications. LEED is a preeminent program for the design, construction and operation of high-performance green buildings. WELL is a building standard focused on enhancing people’s health and wellness through built environments.
Merck invests approximately 20 per cent of total sales in R&D discovery and development each year. In the US, it’s comprised of three businesses including Healthcare, Life Science and Performance Material.